Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Covifenz
- Development stage
- Phase 3
- Lead developer
- Medicago
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Covifenz** is a plant-based, recombinant virus-like-particle COVID-19 vaccine developed by Medicago with GSK's AS03 adjuvant system. It contains plant-produced virus-like particles displaying SARS-CoV-2 original-strain spike protein and is intended to induce antigen-specific neutralizing and cellular immune responses that help prevent COVID-19. Health Canada authorized the two-dose intramuscular vaccine for adults in February 2022; Medicago cancelled the authorization on March 31, 2023, and the product was discontinued before commercial marketing. ([canada.ca](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/medicago.html))
- Brand names
- Covifenz
- Other names
- Plant-derived Coronavirus-Like Particle COVID-19 VaccineMedicago COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Covifenz.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Covifenz.